Floatz logo

Tisleizumab

Metastatic Colorectal Cancer (mCRC)

Tao ZhangPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

839 Active assets in the Metastatic Colorectal Cancer (mCRC) cohort.

Asset / SponsorPhaseRating
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
MARBLE DUST
James Varani
Phase 2/3BB
FLUOROURACILUM
Washington University School of Medicine
Phase 4BB
PANITUMUMAB
M.D. Anderson Cancer Center
Phase 3BB
Cetuximab
Shanghai Henlius Biotech
Phase 4BB

View all 50 →

Same molecule, other indications

Tisleizumab is also rated in:

refractory malignant neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →
Anti PD-1Dormant
CCC
Indicative ·
53 / 100
View asset →
rectal cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →